K156N integrase substitution in combination with 3’PPT resistance mutations against dolutegravir

European Meeting on HIV & Hepatitis 2022

Long-term Efficacy, Safety, and Durability of Ibalizumab-based Regimens in Subgroup of TMB- 202 Participants

European Meeting on HIV & Hepatitis 2022

Residual HIV-1 RNA in 4d on/3d off (ANRS 170 QUATUOR) through W96

European Meeting on HIV & Hepatitis 2022

Switch to ART with BIC/FTC/TAF achieves virological control in patients with low level viremia

European Meeting on HIV & Hepatitis 2022

Implementation of HCV- infection treatment programm with DAA in armenia among HIV- infected patients in COVID-19 era

European Meeting on HIV & Hepatitis 2022

Impacts of Differentiated Service Delivery Model (DSDM) on Adherence (ADH) to clinical appointment Among Children and Adolescent Living with HIV (CALHIV) attending at Mbeya Center of Excellence (COE), Baylor-Tanzania

European Meeting on HIV & Hepatitis 2022

HIV and SARS-CoV-2: the interplay of two wicked problems

European Meeting on HIV & Hepatitis 2022

Eu HIV & Hep Abstracts 2022_56

European Meeting on HIV & Hepatitis 2022

Prevalence and viral load suppression rate among children and adolescents with dual infections (any two of HIV, HBV, and HCV) in Nnewi, Nigeria

European Meeting on HIV & Hepatitis 2022

Proviral DNA for detection of HIV-1 subtype A drug resistance mutations

European Meeting on HIV & Hepatitis 2022

Combined COVID-19 vaccination and hepatitis C virus screening intervention for high-risk populations at a centre for addiction services in Barcelona, Spain

European Meeting on HIV & Hepatitis 2022

Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high- risk populations at a mobile testing unit in Madrid, Spain

European Meeting on HIV & Hepatitis 2022

Community perspectives on self- testing for HIV and HCV in the WHO European region

European Meeting on HIV & Hepatitis 2022

Viral load suppression after three-year Ibalizumab treatment in a multidrug-resistant HIV-1- infected woman: Clinical experience.

European Meeting on HIV & Hepatitis 2022

CASE - HIV+ End-Stage Renal Disease Patient with Immunosuppressive Drug-Drug Interactions Received Successful Transplantation after Ibalizumab Suppressed Switch

European Meeting on HIV & Hepatitis 2022

Clinical course of AIDS with COVID-19 coinfection with prolonged SARS CoV-2 replication despite remdesivir/molnupiravir treatment.

European Meeting on HIV & Hepatitis 2022

A Case of IRIS Syphilis Due to Prozone Effect

European Meeting on HIV & Hepatitis 2022

SARS-CoV-2 antibody seroprevalence in previously undiagnosed persons in Tbilisi, Georgia: Results of three repeated serosurveys

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Rate of HCV reinfection among people living with HCV following successful DAA therapy in Tbilisi, Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

COVID-19 Challenges and Scale-up in Access to Community-based HCV Treatment for HIV/HCV Co-infected PWIDs in Ukraine

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Dynamics and peculiarities of AIDS mortality in Minsk, Belarus

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

“Evaluate potential impact of COVID-19 pandemic on HIV testing and care national program in the republic of Georgia”

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Effect of remdesivir on mortality in patients with COVID-19: A retrospective cohort study

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Integrating viral hepatitis and PrEP services through KP-led clinics in Vietnam: An opportunity to achieve dual elimination of HIV and viral hepatitis by 2030

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021